We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Combining Biomarkers Predicts Metastasis in Medullary Thyroid Carcinoma

By LabMedica International staff writers
Posted on 18 Mar 2020
Medullary thyroid carcinoma (MTC) is a neuroendocrine neoplasm originating from thyroid parafollicular C cells and accounts for only 5% of all thyroid cancers, but its malignancy is relatively high, causing 8% to 13% of thyroid cancer‐related deaths due to its aggressiveness.

It has been reported that MTC can synthesize and secrete a variety of bioactive substances, such as calcitonin (Ctn), carcinoembryonic antigen (CEA), and neuron‐specific enolase (NSE). More...
Numerous reports have shown that the expression levels of Ctn and CEA are related to cervical lymph node metastasis,

Clinical Laboratory Scientists at the Sir Run Run Shaw Hospital (Hangzhou, China) enrolled 74 consecutive patients (39 males and 35 females, mean age 51.4 ± 12.9 years) who underwent surgery for untreated MTC, from January 2013 to April 2019. Fasting blood samples were drawn from all patients before surgery in the morning and transported to the laboratory within three hours after phlebotomizing. Cervical lymph node dissection was performed during thyroidectomy.

Serum Ctn was measured via Siemens IMMULITE 2000 automatic chemiluminescence immunoassay analyzer (Siemens Healthcare Diagnostics Ltd, Erlangen Germany); serum alpha‐fetoprotein (AFP), carbohydrate‐associated antigen 19‐9 (CA19‐9), and CEA were measured by Siemens Centaur XP automatic chemiluminescence immunoassay analyzer; serum cytokeratin 19 fragment (CYFRA21‐1) and NSE were measured by Roche Cobas e 602 automatic electrochemical luminescence immunoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany). Immunohistochemistry was used to make the diagnosis of MTC, if the case was difficult to determine by routine pathology techniques.

The scientists reported that the rate of lateral lymph node metastasis (LLNM) in their study was 48.64% (36/74). The expression levels of serum Ctn, CEA, and NSE in MTC with LLNM were significantly higher than those without LLNM; however, there was no significant difference in the levels of serum AFP, CYFRA21‐1, CA19‐9, and CA242 between the two groups.

The area under the curve (AUC) predicted by serum Ctn, CEA, and NSE for LLNM in MTC patients was 0.867, 0.831, and 0.726, respectively, and the AUC of serum Ctn, CEA, and NSE combined detection was up to 0.89, higher than using a single biomarker. The sensitivity and specificity of serum Ctn, CEA, and NSE combined detection in prediction of LLNM were 88.9% and 81.6%, respectively.

The authors concluded that the concentrations of serum Ctn, CEA, and NSE are closely related to LLNM in MTC, and the combined detection of all three biomarkers has a higher clinical value in the evaluation of MTC patients with LLNM. The study was published on March 6, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Sir Run Run Shaw Hospital
Siemens Healthcare Diagnostics
Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.